Impassion030

This is a global phase III open label, randomized, controlled study designto evaluate the efficacy, safety, and pharmacokinetics of adjuvant treatment with Atezolizumab + T-AC/ECcompared with T –AC/EC alone in patients with newly diagnosed TNBC who have completed surgery with curative intent of their primary tumor

Die Studie eignet sich für:
Patienten mit Triple negativen Mammakarzinom